Table 1. Studies Included in Pooled Analysis.
References | Phase | Patients (n) | Chemotherapy | Median (mo) TTP/PFS | Median OS (mo) |
---|---|---|---|---|---|
Ko et al19 | II | 52 | FDR gemcitabine (1000 mg/m2) day 1 + cisplatin (20 mg/m2) day 1 + bevacizumab (10 mg/kg) day 1; every 2 wk | 6.6 (TTP) | 8.2 |
Javle et al20 | II | 50 | Gemcitabine (1000 mg/m2) day 1-8 + capecitabine (1300 mg/m2) day 1-14 + bevacizumab (15 mg/kg) day 1; every 3 wk | 5.8 (PFS) | 4.8 |
Fogelman et al17 | II | 50 | FDR gemcitabine (1000 mg/m2) day 1 + oxaliplatin (100 mg/m2) day 2 + bevacizumab (10 mg/kg) day 1; every 2 wk | 4.9 (PFS) | 11.9 |
Martin et al16 | II | 42 | FDR gemcitabine (1000 mg/m2) day 1 + infusional 5-fluorouracil (2400 mg/m2) day 1 + bevacizumab (10 mg/kg) day 1; every 2 wk | 5.9 (PFS) | 7.4 |
FDR indicates fixed dose rate; OS, overall survival; PFS, progression free survival; TTP, time to progression.